Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,310 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT03395847 | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma | completed | Early Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05557955 | Identification of Breath Biomarkers in Esophageal Cancer(EC-CRT-005) | completed | — | 210 | Mian XIOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | completed | Phase 3 | 746 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Oct 24, 2023 | clinicaltrials |
| NCT05302011 | Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02971956 | Pembrolizumab in Refractory Advanced Esophageal Cancer | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT01333033 | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy | completed | Phase 2 | 257 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT03918499 | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 9 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT03888092 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | completed | Phase 1 / Phase 2 | 81 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT02564263 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | completed | Phase 3 | 628 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 13, 2023 | clinicaltrials |
| NCT01973725 | Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02976909 | Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 46 | Yuhong LiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02023593 | FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma | completed | Phase 2 | 35 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02350517 | Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | completed | Phase 2 | 52 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02965976 | Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer | completed | Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02976896 | Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment(Poetry-1) | completed | Phase 2 | 43 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04199832 | To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy | completed | — | 156 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04764643 | The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy | completed | N/A | 140 | Xijing Hospital of Digestive DiseasesOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT04293458 | Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE(ESOGUARDBE1) | completed | N/A | 145 | Lucid Diagnostics, Inc.INDUSTRY | 2 | Jan 25, 2023 | clinicaltrials |
| NCT04380480 | Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT03160209 | HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi | completed | — | 600 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT00586872 | Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus | completed | — | 1,000 | Mayo ClinicOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT03762564 | Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy(RAMOS) | completed | Phase 2 | 21 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05628441 | Real-time Computer Aided Detection of Barrett's Neoplasia | completed | — | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT03368196 | DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | completed | Phase 1 | 12 | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyINDUSTRY | 1 | Nov 3, 2022 | clinicaltrials |
| NCT05604950 | Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years | completed | — | 2 | Yongtao HanOTHER | 0 | Nov 3, 2022 | clinicaltrials |
| NCT03660449 | Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04047004 | Adjuvant PIPAC in Gastric Cancer Patients(PIPAC-OPC4) | completed | Phase 1 | 20 | Michael Bau MortensenOTHER | 2 | Oct 6, 2022 | clinicaltrials |
| NCT02513784 | Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome(Mouthwash) | completed | N/A | 20 | Columbia UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04609813 | Esophageal cAncer Screening Trial(EAST) | completed | — | 14,597 | Changhai HospitalOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT02559687 | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | completed | Phase 2 | 121 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 14, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT01938326 | Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG) | completed | N/A | 86 | Seoul National University Bundang HospitalOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT04483349 | Assessment of What Patients and Healthcare Providers Value | completed | — | 397 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02335411 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | completed | Phase 2 | 318 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2022 | clinicaltrials |
| NCT03925870 | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 45 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT04936399 | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom | completed | — | 87 | Bristol-Myers SquibbINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT03409848 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma(INTEGA) | completed | Phase 2 | 97 | AIO-Studien-gGmbHOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT01137123 | Improve the Treatment of Thoracic Esophageal Cancer | completed | Phase 3 | 301 | Sun Yat-sen UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04602299 | Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors | completed | N/A | 2,000 | Changhai HospitalOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01962246 | Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction(A-C) | completed | Phase 2 / Phase 3 | 169 | Hebei Medical UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2023source: clinicaltrials